View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 9, 2022

Sen-Jam initiates subject enrolment in Phase II Covid-19 treatment trial

KVK Tech will offer access to formulation and chemistry, manufacturing, and controls for Sen-Jam’s Covid-19 therapy.

Sen-Jam Pharmaceutical has initiated subject enrolment in the Phase II clinical trial of its investigational oral Covid-19 therapy, SJP-002C, in Nepal. 

Since last year, a joint team of researchers from various countries have been working to obtain approvals to begin the trial with the Nepalese authorities. 

These research activities are the result of the collaboration between Sen-Jam, the Duke-NUS Medical School in Singapore, and Duke University School of Medicine and Global Clinical Research, which together formed a group of global scientists.

Subject enrolment in a clinical trial of SJP-002C under a co-development deal with Duke-NUS and Duke University School of Medicine is underway. 

Sen-Jam collaborated with KVK Tech, the largest strategic investor of the company so far, which will offer access to formulation and chemistry, manufacturing, and controls (CMC) for the Covid-19 therapy.

The partnership with the speciality pharmaceutical manufacturing company will help Sen-Jam quickly produce billions of capsules per year. 

KVK-Tech Business Development director Kiran Vepuri said: “We pride ourselves on our commitment to deliver safe, effective, and affordable FDA-approved pharmaceuticals to meet our customers’ needs and ensure that patients have access to high-quality medicines when they need it. 

“Sen-Jam and their talented team of innovators, scientists, and entrepreneurs represent a perfect fit for our culture of excellence and our unwavering focus on delivering value.”

Sen-Jam focuses on repurposing small molecules for the development of new therapies for large unmet needs to enhance clinical outcomes.

In August last year, the company partnered with Duke-NUS Medical School to begin a Phase II trial of SJP-002C for Covid-19 in Nepal.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU